Published on May 27, 2014

India is noted as the fastest budding market in the world and there is no such country in the world where the Indian pharmaceutical products have not yet reached, also the integrity and quality of the Indian medical products are according to the international standard. This industry is noted as an emerging global leader with raising concerns in the world for its global equivalent, in other parts of the world including the US.

Over the past two decades, significant amount of attention has been attracted by the Indian pharma industries and due to strong generic pharma position of India most of the companies have aggressively joined hands with the Indian companies. However, owing to a number of limitations in the FDI policy in spite of significant global interest, size of investments in the space of Indian pharma by global companies had remained constrained.

On an issues with the US, the drug manufacturers sector expects new government to take a tough stand and once a new government headed by Narendra Modi takes up the charge, the pharma industry groups as well as individual companies will be gearing up with their presentation, to be commenced with minister and at the office of Prime Minister.

Currently in its Special 301 termed report, the US Trade Representative (USTR) on an Intellectual Property Rights (IPR) had kept India on its priority watch list of suspected violators of the US patents law. Moreover, the USTR to promote rendezvous and progress on IPR challenges which are identified in the 2014 review of India had announced that it would demeanor an out-of-cycle review.

According to a new global report, in compare to last year the pharmaceutical sales in India by the year 2016 will rise by 14.4% to USD 27 billion, furthermore as a percent of health care expenditures by the year 2016 is expected to reach by 27%. As per the forecasts made by the Bank of America Merrill Lynche, in the third quarter of 2014 the pharma sector will be witnessing the sales growth of 26%.